Aglatimagene besadenovec
- Generic Name
- Aglatimagene besadenovec
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1621271-62-2
- Unique Ingredient Identifier
- 5Z72SSS34W
- Background
Aglatimagene besadenovec is under investigation in clinical trial NCT00638612 (AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)).
- Associated Conditions
- -
- Associated Therapies
- -
Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 180
- Registration Number
- NCT03313596
- Locations
- 🇨🇳
The Third XiangYa Hospital of Central South University, Changsha, China
🇨🇳West China Hospital of Sichuan University, Chengdu, China
🇨🇳The Third Affiliated Hospital,Sun Yat-sen University, Guangzhou, China
Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 81
- Registration Number
- NCT02202564
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath